摘要
NVP-BEZ235是ATP竞争性的PI3K/m TOR双靶点抑制剂,可以通过周期阻滞和凋亡诱导作用在体外水平有效抑制肿瘤细胞的增殖。然而,临床前动物实验发现NVP-BEZ235单药治疗的抗肿瘤效果并不理想。但是,NVPBEZ235与多种抗肿瘤药物联合应用时可以产生强大的协同效应,以NVP-BEZ235为基础的联合化疗方案可能成为肿瘤治疗的新策略。
NVP-BEZ235,a novel dual PI3 K / m TOR inhibitor,has exhibited significant anti-proliferative activity in a great variety of cancer types in vitro by inducing cell-cycle arrest and apoptosis. Disappointingly,NVPBEZ235 monotherapy have not yielded satisfactory results in preclinical models. However,compared with every single agent alone,improved anti-tumor activity can often be achieved when NVP-BEZ235 combined with other cancer therapeutics. In this regard,NVP-BEZ235 in combination with chemotherapeutic drugs is a potential therapeutic strategy.
出处
《基础医学与临床》
CSCD
2016年第10期1450-1454,共5页
Basic and Clinical Medicine
基金
上海市宝山区科学技术委员会项目(12-E-2)
